Bijblijven

, Volume 34, Issue 2, pp 117–128 | Cite as

Behandeling met biologicals bij systeemziekten en ILD

Article
  • 5 Downloads

Samenvatting

Sommige patiënten met therapieresistente chronische sarcoïdose komen in aanmerking voor een derdelijns behandeling met TNF-alfaremmers. Middelen zoals infliximab en adalimumab zijn beide effectief gebleken in de behandeling van patiënten met chronische therapieresistente sarcoïdose.

Bij collageen-vasculaire ziekten geassocieerd met ernstige therapieresistente interstitiële longafwijkingen wordt door de longarts met name de biological rituximab voorgeschreven.

Door onderdrukking van het immuunsysteem bij het gebruik van TNF-alfaremmers zijn patiënten gevoeliger voor infecties of voor reactivatie van latente infecties (bijvoorbeeld tuberculose) en kunnen infecties atypisch en/of acuut verlopen. Bij tekenen van infectie is het wenselijk dat de huisarts contact opneemt met de behandelend longarts. Tevens kunnen patiënten die TNF-alfaremmers gebruiken antilichamen vormen. Dit vermindert de werking van het medicijn en kan allergische reacties veroorzaken.

Het is de verwachting dat het gebruik van biologicals in de toekomst alleen maar zal toenemen, zodat ook de huisarts in zijn of haar praktijk hiermee vaker geconfronteerd zal worden.

Literatuur

  1. 1.
    Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2011;305(4):391–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973;107(4):609–14.CrossRefPubMedGoogle Scholar
  4. 4.
    James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967;2(7515):526–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5‑year pulmonary function. Chest. 2002;121(1):24–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142(6 Pt 1):1268–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–6.PubMedGoogle Scholar
  8. 8.
    Vorselaars AD, Wuyts WA, Vorselaars VM, Zanen P, Deneer VH, Veltkamp M, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest. 2005;127(1):251–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Matej R, Smetakova M, Vasakova M, Novakova J, Sterclova M, Kukal J, et al. PAR-2, IL-4R, TGF-beta and TNF-alpha in bronchoalveolar lavage distinguishes extrinsic allergic alveolitis from sarcoidosis. Exp Ther Med. 2014;8(2):533–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Vorselaars AD, Crommelin HA, Deneer VH, Meek B, Claessen AM, Keijsers RG, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Bois R du, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.CrossRefPubMedGoogle Scholar
  15. 15.
    Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63(3):318–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Cohen Aubart F, Bouvry D, Galanaud D, Dehais C, Mathey G, Psimaras D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264(5):891–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Orum M, Hilberg O, Krag S, Bendstrup E. Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J. 2012;59(12):A4535.PubMedGoogle Scholar
  19. 19.
    Croft AP, Situnayake D, Khair O, Giovanni G, Carruthers D, Sivaguru A, et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin Rheumatol. 2012;31(6):1013–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatr. 2010;81(3):241–6.CrossRefGoogle Scholar
  21. 21.
    Riancho-Zarrabeitia L, Calvo-Rio V, Blanco R, Mesquida M, Adan AM, Herreras JM, et al. Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Vorselaars AD, Verwoerd A, Moorsel CH van, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.CrossRefPubMedGoogle Scholar
  25. 25.
    Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Crommelin HA, Burg LM van der, Vorselaars AD, Drent M, Moorsel CH van, Rijkers GT, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.CrossRefPubMedGoogle Scholar
  28. 28.
    Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128(2):1062–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124(1):177–85.CrossRefPubMedGoogle Scholar
  30. 30.
    Vieira MA, Saraiva MI, Silva LK, Fraga RC, Kakizaki P, Valente NY. Development of exclusively cutaneous sarcoidosis in patient with rheumatoid arthritis during treatment with etanercept. Rev Assoc Med Bras. 1992;62(8):718–20.CrossRefGoogle Scholar
  31. 31.
    Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26(11):1969–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Zidi I, Mestiri S, Bartegi A, Amor NB. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27(2):185–98.CrossRefPubMedGoogle Scholar
  33. 33.
    Callejas-Rubio JL, Lopez-Perez L, Ortego-Centeno N. Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag. 2008;4(6):1305–13.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gilca GE, Diaconescu S, Balan GG, Timofte O, Stefanescu G. Sarcoidosis associated with infliximab therapy in ulcerative colitis: a case report. Medicine (Baltimore). 2017;96(10):e6156.CrossRefGoogle Scholar
  35. 35.
    Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRefGoogle Scholar
  36. 36.
    Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26(3):471–5.PubMedGoogle Scholar
  37. 37.
    Baha A, Hanazay C, Kokturk N, Turktas H. A case of Sarcoidosis associated with anti-tumor necrosis factor treatment. J Investig Med High Impact Case Rep. 2015;3(1):2324709615571366.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-alpha: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol. 2015;29(11):2104–11.CrossRefPubMedGoogle Scholar
  39. 39.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76.CrossRefPubMedGoogle Scholar
  40. 40.
    Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305–12.CrossRefPubMedGoogle Scholar
  42. 42.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44.CrossRefPubMedGoogle Scholar
  43. 43.
    Yonekura CL, Oliveira RDR, Titton DC, Ranza R, Ranzolin A, Hayata AL, et al. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoracao de Terapias Biologicas – BiobadaBrasil). Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):477–83.CrossRefPubMedGoogle Scholar
  44. 44.
    Dapavo P, Vujic I, Fierro MT, Quaglino P, Sanlorenzo M. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(4):736–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6.PubMedGoogle Scholar
  47. 47.
    Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.CrossRefPubMedGoogle Scholar
  49. 49.
    Schimmelpennink MC, Vorselaars ADM, Beek FT van, Crommelin HA, Deneer VHM, Keijsers RGM, Veltkamp M. Efficacy and safety of infliximab biosimilar Inflectra in severe sarcoidosis. Respir Med. 2018;pii:S0954-6111(18)30038-6.  https://doi.org/10.1016/j.rmed.2018.02.009.Google Scholar
  50. 50.
    Wells AU, Denton CP. Interstitial lung disease in connective tissue disease – mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.CrossRefPubMedGoogle Scholar
  51. 51.
    Voortman M, Borg EJ ter, Kruizen AA, Radstake TR, Zanen P, Jong PA de, Heuvel D van den, Grutters JC. Interstitial lung disease in patients with Sjogren’s syndrome: correlation of radiology, pathology, and clinical phenotype. Poster session presented at the American Thoracic Society; Washington D.C. 2017.Google Scholar
  52. 52.
    Khanna D, Denton CP, Lin CJ, Laar JM van, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faScinate). Ann Rheum Dis. 2018;77(2):212–20.CrossRefPubMedGoogle Scholar
  53. 53.
    Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814–24.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Smith V, Piette Y, Praet JT van, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Jordan S, Distler JH, Maurer B, Huscher D, Laar JM van, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–94.CrossRefPubMedGoogle Scholar
  56. 56.
    Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71.CrossRefGoogle Scholar
  57. 57.
    Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Keir GJ, Maher TM, Ming D, Abdullah R, Lauretis A de, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420–8.CrossRefGoogle Scholar
  61. 61.
    Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016;55(7):1318–24.CrossRefGoogle Scholar
  62. 62.
    Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32(4):296–304.PubMedGoogle Scholar
  63. 63.
    Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol. 2017;23(8):411–5.CrossRefPubMedGoogle Scholar
  64. 64.
    Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.CrossRefGoogle Scholar
  65. 65.
    Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275.  https://doi.org/10.1186/s13063-017-2016-2.CrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum is een imprint van Springer Media B.V., onderdeel van Springer Nature 2018

Authors and Affiliations

  1. 1.Nieuwegein/UtrechtNederland

Personalised recommendations